Nova Patents
IS6794A

Polymeric delivery formulations of leuprolide with improved efficacy

Abstract

The present invention is directed to a flowable composition that is suitable for use as a controlled release implant. The flowable composition includes a biodegradable thermoplastic polyester that is at least substantially insoluble in aqueous medium or body fluid. The flowable composition also includes a biocompatible polar aprotic solvent. The biocompatible polar aprotic solvent is miscible to dispersible in aqueous medium or body fluid. The flowable composition also includes leuprolide acetate. The present invention is also directed to a method for forming the flowable composition. The present invention is also directed to a biodegradable implant formed in situ, in a patient. The biodegradable implant is formed by injecting a flowable composition within the body of the patient and allowing the biocompatible polar aprotic solvent to dissipate to produce a solid biodegradable implant. The present invention is also directed to a method of forming a biodegradable implant in situ, in a living patient. The method includes injecting a flowable composition within the body of a patient and allowing the biocompatible polar aprotic solvent to dissipate to produce a solid biodegradable implant. The present invention is also directed to a method of treating cancer in a patient. The method includes administering to the patient in need of such treatment an effective amount of a flowable composition of the present invention. The present invention is also directed to a method of reducing LHRH levels in a patient. The method includes administering to the patient in need of such LHRH reduction an effective amount of a flowable composition of the present invention. The present invention is also directed to a kit. The kit includes a first container and a second container. The first container includes a composition that includes a biodegradable thermoplastic polyester and a biocompatible polar aprotic solvent. The second container includes leuprolide acetate. The present invention is also directed to a solid implant. The solid implant includes a biocompatible thermoplastic polyester and leuprolide acetate. The solid implant has a solid or gelatinous microporous matrix, wherein the matrix is a core surrounded by a skin. The solid implant can further include a biocompatible organic solvent.

Term

Term ended

Projected expiry passed 23 April 2023, 3.4 years ago.

  1. Priority
  2. Filed and published
  3. Projected expiry
  4. Today

124 members in 27 offices

This recordMember, by publication datePriority claim17 more offices are in the list below

Priority claims8

Priority claims
DocumentOfficeKindDate
66617400United States of AmericaA
66617400United States of AmericaA
71175800United States of AmericaA
71175800United States of AmericaA
09666174–––
09711758–––
US20000666174–––
US20000711758–––

Members124

Family members, oldest first
DocumentOfficeKind
CA2348016A1CanadaA1
WO0024374A1World Intellectual Property Organization (WIPO)A1
AU1331200AAustraliaA
US6143314AUnited States of AmericaA
EP1126822A1European Patent Office (EPO)A1
IL142470D0IsraelD0
CA2436275A1CanadaA1
WO0230393A2World Intellectual Property Organization (WIPO)A2
AU9293101AAustraliaA
WO0230393A3World Intellectual Property Organization (WIPO)A3
JP2002528403AJapanA
IS6794AThis recordIcelandA
US6565874B1United States of AmericaB1
EP1322286A2European Patent Office (EPO)A2
US2003133964A1United States of AmericaA1
KR20030064401ARepublic of KoreaA
SK5152003A3SlovakiaA3
US6630155B1United States of AmericaB1
IL155006D0IsraelD0
CZ20031124A3CzechiaA3
HU0302981A2HungaryA2
HUP0302981A2HungaryA2
BR0114069ABrazilA
CN1474685AChinaA
EP1126822B1European Patent Office (EPO)B1
AT259217TAustriaT
ATE259217T1AustriaT1
DE69914787D1GermanyD1
JP2004510807AJapanA
DK1126822T3DenmarkT3
PT1126822EPortugalE
US6773714B2United States of AmericaB2
ZA200302944BSouth AfricaB
PL361671A1PolandA1
NZ525210ANew ZealandA
ES2219079T3SpainT3
US2004229912A1United States of AmericaA1
DE69914787T2GermanyT2
EP1322286B1European Patent Office (EPO)B1
AT296088TAustriaT
ATE296088T3AustriaT3
DE60111068D1GermanyD1
DK1322286T3DenmarkT3
PT1322286EPortugalE
MXPA03002552AMexicoA
EP1586309A1European Patent Office (EPO)A1
SI1322286T1SloveniaT1
ES2241876T3SpainT3
DE60111068T2GermanyT2
RU2271826C2Russian FederationC2
HU0302981A3HungaryA3
HUP0302981A3HungaryA3
CA2348016CCanadaC
AU2001292931B2AustraliaB2
AU2006241376A1AustraliaA1
CA2436275CCanadaC
IL142470AIsraelA
US2007104759A1United States of AmericaA1
IL155006AIsraelA
KR100831113B1Republic of KoreaB1
US2008194663A1United States of AmericaA1
CN100536922CChinaC
AU2006241376B2AustraliaB2
EP1586309B1European Patent Office (EPO)B1
EP2158900A1European Patent Office (EPO)A1
AT458469TAustriaT
ATE458469T3AustriaT3
CN101669900AChinaA
DE60141421D1GermanyD1
AU2010201645A1AustraliaA1
PT1586309EPortugalE
DK1586309T3DenmarkT3
ES2341777T3SpainT3
US2010226954A1United States of AmericaA1
US2010234305A1United States of AmericaA1
HK1139596A1Hong Kong, ChinaA1
HK1141459A1Hong Kong, ChinaA1
SK287528B6SlovakiaB6
CY1106045T1CyprusT1
JP4686653B2JapanB2
JP2012012418AJapanA
CZ303134B6CzechiaB6
AU2010201645B2AustraliaB2
EP2158900B1European Patent Office (EPO)B1
DK2158900T3DenmarkT3
PT2158900EPortugalE
HU228386B1HungaryB1
ES2404559T3SpainT3
US8470359B2United States of AmericaB2
US8486455B2United States of AmericaB2
CN101669900BChinaB
US2013303722A1United States of AmericaA1
JP2013253101AJapanA
US8840916B2United States of AmericaB2
US2014357574A1United States of AmericaA1
JP2014240439AJapanA
US2015150937A1United States of AmericaA1
CY1110653T1CyprusT1
US9254307B2United States of AmericaB2
US9283282B2United States of AmericaB2
Showing 100 of 124